Cypress Capital Management LLC WY Acquires Shares of 1,400 GRAIL, Inc. $GRAL

Cypress Capital Management LLC WY acquired a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,400 shares of the company’s stock, valued at approximately $72,000.

A number of other large investors have also modified their holdings of the stock. Cerity Partners LLC purchased a new stake in shares of GRAIL during the 1st quarter valued at about $394,000. Arizona State Retirement System acquired a new stake in GRAIL in the first quarter valued at approximately $220,000. Westmount Partners LLC purchased a new stake in shares of GRAIL during the first quarter valued at approximately $205,000. CWM LLC raised its stake in shares of GRAIL by 248.3% during the first quarter. CWM LLC now owns 22,715 shares of the company’s stock valued at $580,000 after purchasing an additional 16,193 shares during the period. Finally, Slow Capital Inc. lifted its position in shares of GRAIL by 2.0% during the first quarter. Slow Capital Inc. now owns 135,957 shares of the company’s stock worth $3,472,000 after purchasing an additional 2,673 shares in the last quarter.

GRAIL Trading Down 0.8%

Shares of NASDAQ:GRAL opened at $79.40 on Friday. The firm has a market cap of $2.86 billion, a PE ratio of -6.06 and a beta of 4.31. The company has a fifty day simple moving average of $61.90 and a 200 day simple moving average of $46.53. GRAIL, Inc. has a 12-month low of $13.58 and a 12-month high of $103.00.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) EPS for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). The company had revenue of $35.54 million for the quarter, compared to the consensus estimate of $37.57 million. GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. As a group, equities research analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on GRAL shares. Canaccord Genuity Group upped their target price on shares of GRAIL from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Wednesday, October 8th. Finally, UBS Group set a $75.00 target price on GRAIL in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, GRAIL has an average rating of “Hold” and a consensus price target of $60.00.

Insider Transactions at GRAIL

In related news, President Joshua J. Ofman sold 81,385 shares of GRAIL stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $62.50, for a total value of $5,086,562.50. Following the completion of the transaction, the president directly owned 396,797 shares in the company, valued at approximately $24,799,812.50. This trade represents a 17.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Ragusa sold 7,239 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $68.88, for a total value of $498,622.32. Following the sale, the chief executive officer owned 727,388 shares in the company, valued at $50,102,485.44. The trade was a 0.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 117,497 shares of company stock valued at $7,515,436 over the last quarter. Insiders own 1.85% of the company’s stock.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.